Latest Innovation News

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

NoviqTech's December quarter report reveals a strategic $1.05 million capital raise, a significant HBAR token purchase, and expanding partnerships that position the company at the forefront of blockchain-powered sustainability solutions.

Connexion Mobility reports a robust half-year performance with 15% revenue growth and a 43% jump in net profit, driven by product innovation and expanding dealership engagement.

Meteoric Resources NL has reported a significant update to its Caldeira Rare Earth Project, highlighting improved financial metrics and exceptional drilling results that reinforce its position as a low-cost rare earths producer.

Li-S Energy has set a new benchmark in lithium-sulfur battery technology, achieving a record 456Wh/kg energy density and successfully powering its first UAV test flights, signaling strong momentum in sustainable battery innovation.

Evolution Energy Minerals has initiated siteworks at its Chilalo Graphite Project in Tanzania, appointed George Donne as CEO, and identified a promising new copper-lead-zinc prospect, positioning the company for a Final Investment Decision in 2025.

MONEYME reports a 54% surge in loan originations and a $1.4 billion loan book in 2Q25, underpinned by fresh growth capital and a strategic shift to secured lending.

Propell Holdings has reported its first half-year cash profit since its 2021 ASX listing, driven by loan book growth and new product launches, despite a Q2 operating cash outflow.

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.